Clinical Overview > Condition/ Syndrome
Search for other papers by Marianne Geilswijk in
Google Scholar
PubMed
Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Lise Lotte Andersen in
Google Scholar
PubMed
Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Morten Frost in
Google Scholar
PubMed
Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Klaus Brusgaard in
Google Scholar
PubMed
Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Henning Beck-Nielsen in
Google Scholar
PubMed
Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Anja Lisbeth Frederiksen in
Google Scholar
PubMed
Departments of Endocrinology, Odense University Hospital, Odense, Denmark
Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Dorte Møller Jensen in
Google Scholar
PubMed
Summary
Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest that octreotide treatment in pregnancy, as well as hypoglycemia in itself, may pose a risk of fetal growth restriction. During pregnancy, management of blood glucose levels in familial hyperinsulinemic hypoglycemia thus forms a medical dilemma. We report on pregnancy outcomes in a woman with symptomatic familial hyperinsulinemic hypoglycemia, type 3. During the patient’s first pregnancy with a viable fetus octreotide treatment was instituted in gestational age 23 weeks to prevent severe hypoglycemic incidences. Fetal growth velocity declined, and at 37 weeks of gestation, intrauterine growth retardation was evident. During the second pregnancy with a viable fetus, blood glucose levels were managed through dietary intervention alone. Thus, the patient was advised to take small but frequent meals high in fiber and low in carbohydrates. Throughout pregnancy, no incidences of severe hypoglycemia occurred and fetal growth velocity was normal. We conclude that octreotide treatment during pregnancy may pose a risk of fetal growth restriction and warrants careful consideration. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only, also during pregnancy.
Learning points:
-
Gain-of-function mutations in GCK cause familial hyperinsulinemic hypoglycemia.
-
Hypoglycemia during pregnancy may have serious health implications for mother and fetus.
-
Pregnancy with hyperinsulinism represents a medical dilemma as hypoglycemia as well as octreotide treatment may pose a risk of fetal growth restriction.
-
In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only.